New Study Shows DABRA Laser System Achieved 94% Success Rate in Patients with Peripheral Artery Disease

gbaf1news

Ra Medical Systems, Inc. (NYSE: RMED), today announced study results from Athar Ansari, MD, Director of the California Heart & Vascular Clinic, who stated, DABRA is fundamentally changing the way I practice medicine. Dr. Ansaris study demonstrated a 94% success rate treating peripheral artery disease (PAD) by ablating arterial blockages. He presented his findings at this years Joint Interventional Meeting in Milan, Italy.

In Dr. Ansaris study, 292 lesions were treated in 200 patients at his outpatient office-based lab in El Centro, Calif., an area with high diabetes, peripheral artery disease, and amputation rates. In my experience, DABRA delivers results rapidly and safely, even in challenging cases, said Dr. Ansari. DABRA can treat all types of plaques in arteries above and below the knee. Patients are discharged in two to three hours, allowing them to quickly return to their daily lives. Most importantly, DABRA meets the need for safe, high-quality tools in smaller-scale settings, including office-based labs, allowing me to spare patients from hospital stays and reduce costs.

DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) is a novel, minimally invasive excimer laser system that non-thermally, photochemically ablates channels in vascular blockages. Unlike many treatments for PAD that may damage the arterial wall, DABRA treats blockages with minimal vascular trauma.

We believe Dr. Ansaris study and experience are further evidence that DABRA benefits patients, physicians, and the healthcare system as a whole, added Dean Irwin, Ra Medical Systems CEO. We are delivering on our mission to provide physicians a better treatment to save limbs and lives in the U.S. and around the world.

About Ra Medical Systems

Ra Medical Systems is a commercial medical device company developing and marketing innovative excimer laser systems for the treatment of vascular and dermatologic diseases. DABRA launched in 2017 for the endovascular treatment of blockages resulting from lower extremity vascular disease. Pharos launched in 2004 for the treatment of dermatological disorders including psoriasis, vitiligo, and atopic dermatitis. DABRA and Pharos are based on Ra Medicals core excimer laser technology platform that produces 308 nanometer light, a UVB wavelength that studies have demonstrated increases T-cell apoptosis, or cell death, which may produce a beneficial, targeted immunosuppressive effect. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Ra Medical’s future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential benefits to patients and physicians using the DABRA catheter and laser system. Ra Medical’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medicals products; the Companys ability to effectually manage inventory; Ra Medicals ability to recruit and retain management and key personnel; Ra Medicals need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medicals industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medicals news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical’s business and operating results is contained in Ra Medicals final prospectus relating to its initial public offering and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Media Contacts
Caitlin Kasunich / Tony Forde
KCSA
Strategic Communications
212.896.1241 / 347.487.6218
[email protected]
/ [email protected]

Investor Contact
Jeffrey Kraws
President, Ra Medical
Systems
760.707.7516
[email protected]